Colgate-Palmolive Company (CL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 May, 2026Opening remarks and agenda
The meeting opened with a welcome from the Chairman, President, and CEO, outlining the agenda and introducing board members and new director Christopher Boerner.
The formal business included five voting items, followed by a review of 2025 performance, the 2030 strategy, and a Q&A session.
Board and executive committee updates
Christopher Boerner, with significant pharmaceutical and healthcare experience, joined the board in 2026.
Jennifer Daniels, Chief Legal Officer and Secretary, is retiring after 11 years of service.
Shareholder proposals
Proposal to remove diversity from board candidate considerations was presented and debated; the board opposed it, emphasizing the value of diverse perspectives.
Proposal for an independent board chairman was discussed; the board recommended against it, citing effective current governance and flexibility.
Latest events from Colgate-Palmolive Company
- Net sales up 8.4% to $5.3B, with strong growth in Latin America and EMEA offsetting higher costs.CL
Q1 20261 May 2026 - Director elections, auditor ratification, and key shareholder proposals headline the annual meeting.CL
Proxy filing16 Apr 2026 - Board recommends supporting company proposals, highlights strong governance, and opposes two shareholder proposals.CL
Proxy filing25 Mar 2026 - Board recommends voting for all directors and auditor, against DEI removal and independent chair.CL
Proxy filing25 Mar 2026 - 2030 strategy targets growth through premium innovation, digital scale, and agile execution.CL
UBS Global Consumer and Retail Conference11 Mar 2026 - 2030 strategy leverages innovation, AI, and omni-channel execution to drive global growth and ROI.CL
Consumer Analyst Group of New York Conference (CAGNY) 202620 Feb 2026 - Premiumization, innovation, and digital transformation drive growth amid global volatility.CL
2025 dbAccess Global Consumer Conference3 Feb 2026 - Q2 2024 saw 4.9% sales growth, margin expansion, and upgraded full-year guidance.CL
Q2 20242 Feb 2026 - 2025 sales rose 1.4% with record cash flow; 2026 outlook targets higher EPS and innovation.CL
Q4 20252 Feb 2026